TY PHAR.(SZ:002728)2025-08-22 13:42Group 1: Marketing Reform and Sales Recovery - The company has completed a comprehensive upgrade of its marketing organization, resulting in a net increase of over 100 frontline sales personnel since the reform began [3] - Sales of the core product "Te Yi" cough syrup reached 331 million pieces, recovering to 61.29% of the same period in 2023, indicating a gradual release of market demand [4] - The company invested 172 million yuan in brand building during the reporting period, enhancing brand awareness among younger and online consumer groups [4] Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 491.43 million yuan, a year-on-year increase of 56.54% [5] - The net profit attributable to shareholders reached 38.01 million yuan, a significant year-on-year increase of 1313.23%, demonstrating strong profit recovery capabilities [5] Group 3: Future Sales Growth and Market Potential - The company aims to achieve annual sales of 1 billion boxes of cough syrup within 3-5 years post-reform, with a projected annual compound growth rate of nearly 20% [6][8] - The cough syrup has a production capacity of 1.8 billion pieces, which can be expanded to 2.4 billion pieces based on market demand [9] Group 4: Online Sales and Marketing Strategy - Online sales of the cough syrup are currently small but are expected to grow rapidly due to changing consumer habits and increased support from online platforms [11] - In the first half of 2025, the cough syrup's sales on various platforms showed significant growth, with a 652% year-on-year increase on JD.com and a 260% increase on Alibaba [12] Group 5: Brand Promotion and Advertising - The company has shifted its advertising strategy from traditional media to a combination of traditional and new media, increasing brand promotion efforts [15] - The advertising budget will continue to grow in the coming years, focusing on the "Te Yi" cough syrup while aiming to optimize the sales expense structure [16] Group 6: Product Development and Market Expansion - The company plans to actively promote the skin disease blood toxin pill as a major product following the cough syrup, leveraging existing sales channels [12] - The company will continue to explore external growth opportunities, including potential mergers or partnerships that align with its strategic goals [17]